**Supplemental Table: Interrupted Time Series Model Parameters**

|  |
| --- |
| **Model =** log(DOT) = log(pd) + B0 + B1\*time+ B2\*intervention+B3\*time\_past\_intervention |
| **Antibiotic** | **Parameter** | **Estimate** | **Confidence Limits** | **P Value** |
| Fluoroquinolones | Trend Before July 2016 (eB1) | 0.9934 | 0.9907 | 0.9961 | <.0001 |
|  | Immediate Change (e­B2) | 0.9235 | 0.8775 | 0.9718 | 0.0022 |
|  | Trend After July 2016 (eB1+B3) | 0.9914 | 0.9841 | 0.9988 | 0.0221 |
| Atypicals | Trend Before July 2016 (eB1) | 0.9966 | 0.9918 | 1.0014 | 0.1677 |
|  | Immediate Change (e­B2) | 0.9671 | 0.8999 | 1.0393 | 0.3627 |
|  | Trend After July 2016 (eB1+B3) | 1.0187 | 1.012 | 1.0254 | <.0001 |
| Aztreonam | Trend Before July 2016 (eB1) | 1.0182 | 1.0066 | 1.03 | 0.0021 |
|  | Immediate Change (e­B2) | 0.9846 | 0.8577 | 1.1302 | 0.8251 |
|  | Trend After July 2016 (eB1+B3) | 0.9916 | 0.9758 | 1.0076 | 0.3032 |
| 1st Gen Ceph. | Trend Before July 2016 (eB1) | 1.0046 | 0.999 | 1.0102 | 0.1106 |
|  | Immediate Change (e­B2) | 0.9706 | 0.847 | 1.1123 | 0.6681 |
|  | Trend After July 2016 (eB1+B3) | 1.0035 | 0.9912 | 1.016 | 0.5771 |
| 2nd Gen Ceph. | Trend Before July 2016 (eB1) | 1.0145 | 1.0045 | 1.0246 | 0.0043 |
|  | Immediate Change (e­B2) | 0.7225 | 0.552 | 0.9456 | 0.0179 |
|  | Trend After July 2016 (eB1+B3) | 1.0096 | 0.9928 | 1.0267 | 0.2637 |
| 3rd Gen Ceph. | Trend Before July 2016 (eB1) | 1.0105 | 0.9863 | 1.0354 | 0.3978 |
|  | Immediate Change (e­B2) | 1.017 | 0.792 | 1.306 | 0.8948 |
|  | Trend After July 2016 (eB1+B3) | 1.0355 | 1.0149 | 1.0565 | 0.0007 |
| Comm-Onset  | Trend Before July 2016 (eB1) | 0.9949 | 0.9906 | 0.9992 | 0.0193 |
|  | Immediate Change (e­B2) | 1.0225 | 0.9762 | 1.071 | 0.346 |
|  | Trend After July 2016 (eB1+B3) | 1.006 | 1.0013 | 1.0108 | 0.0123 |
| Ceftriaxone | Trend Before July 2016 (eB1) | 0.997 | 0.993 | 1.0011 | 0.1527 |
|  | Immediate Change (e­B2) | 1.0059 | 0.9493 | 1.0659 | 0.8415 |
|  | Trend After July 2016 (eB1+B3) | 1.0082 | 1.0032 | 1.0133 | 0.0014 |
| Cefotaxime | Trend Before July 2016 (eB1) | 0.9732 | 0.9602 | 0.9863 | <.0001 |
|  | Immediate Change (e­B2) | 1.0709 | 0.6619 | 1.7324 | 0.7802 |
|  | Trend After July 2016 (eB1+B3) | 0.9443 | 0.8972 | 0.994 | 0.0284 |
| Ertapenem | Trend Before July 2016 (eB1) | 0.9824 | 0.9712 | 0.9937 | 0.0024 |
|  | Immediate Change (e­B2) | 1.1352 | 0.9407 | 1.3698 | 0.186 |
|  | Trend After July 2016 (eB1+B3) | 0.9914 | 0.9741 | 1.0089 | 0.3327 |
| Anti-Pseud. BL | Trend Before July 2016 (eB1) | 1.0029 | 0.9995 | 1.0062 | 0.0908 |
|  | Immediate Change (e­B2) | 1.0036 | 0.9581 | 1.0512 | 0.8795 |
|  | Trend After July 2016 (eB1+B3) | 1.0001 | 0.9962 | 1.004 | 0.9594 |
| Cephamycins | Trend Before July 2016 (eB1) | 0.9971 | 0.986 | 1.0082 | 0.6022 |
|  | Immediate Change (e­B2) | 1.0098 | 0.7801 | 1.3072 | 0.9408 |
|  | Trend After July 2016 (eB1+B3) | 0.9837 | 0.9681 | 0.9997 | 0.0453 |
| Aminoglycosides | Trend Before July 2016 (eB1) | 0.9953 | 0.9904 | 1.0003 | 0.0633 |
|  | Immediate Change (e­B2) | 0.9504 | 0.8174 | 1.1051 | 0.5086 |
|  | Trend After July 2016 (eB1+B3) | 0.9881 | 0.9783 | 0.9979 | 0.0181 |
| Nitrofurantoin | Trend Before July 2016 (eB1) | 0.991 | 0.9839 | 0.9981 | 0.0132 |
|  | Immediate Change (e­B2) | 1.0559 | 0.8553 | 1.3035 | 0.6127 |
|  | Trend After July 2016 (eB1+B3) | 1.0029 | 0.9871 | 1.019 | 0.7221 |
| Oral UTI Therapy | Trend Before July 2016 (eB1) | 1.0007 | 0.9967 | 1.0047 | 0.7432 |
|  | Immediate Change (e­B2) | 0.9097 | 0.8149 | 1.0155 | 0.0917 |
|  | Trend After July 2016 (eB1+B3) | 1.0119 | 1.0014 | 1.0224 | 0.0264 |
| Trimethoprim/Sulfa | Trend Before July 2016 (eB1) | 0.9936 | 0.9883 | 0.9989 | 0.0183 |
|  | Immediate Change (e­B2) | 0.9698 | 0.831 | 1.1317 | 0.6968 |
|  | Trend After July 2016 (eB1+B3) | 1.0021 | 0.9906 | 1.0137 | 0.7191 |
| Amp/Sulb+Amox/Clav | Trend Before July 2016 (eB1) | 1.0046 | 1.0004 | 1.0088 | 0.0316 |
|  | Immediate Change (e­B2) | 0.8767 | 0.7856 | 0.9784 | 0.0187 |
|  | Trend After July 2016 (eB1+B3) | 1.0148 | 1.0049 | 1.0249 | 0.0035 |